StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 7.7
Power Rank trend -> Falling
03/27/2025 16:24:00 EST
Lantheus Holdings Inc (LNTH)
Industry: Drug Manufacturers - Specialty & Generic
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, LNTH has been trading in a range between $110.01 and $91.49 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
LNTH is trading between resistance at $106.36 about 10% to the upside and support at $96.66 -0% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $116.69, about a 20% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Lantheus Holdings Inc $LNTH entered a Green zone 20 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $134.6923, a potential upside of 36.84% from the recent price of 98.43. The stock is trading 28.91% (potential upside) below its 52 week high of $126.89 and 69.24 % (potential downside) above its 52 week low of $58.16 - based on the recent price.
Company Summary
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
News
| Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry Lantheus Holdings, Inc.'s stock has surged 55% since my last “Buy” rating, driven by strong revenue growth from Pylarify and Definity, and a profitable business model. Strategic acquisitions, including Life Molecular Imaging and Evergreen Theragnostics, have diversified Lantheus' pipeline, targeting new markets like Alzheimer's diagnostics and oncology therapeutics. Pylarify's potential patent expiration in 2026 poses a risk, but management is actively seeking to extend protections and diversify revenue streams. Source: Seeking Alpha Fri, 07 Mar 2025 11:12:21 -0500 Sentiment: Positive |
| Lantheus' Pylarify Hit $1B in 2024 Sales Lantheus Holdings (LNTH -1.07%) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic transactions. Source: The Motley Fool Thu, 27 Feb 2025 11:02:28 -0500 Sentiment: Neutral |
| Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call Transcript Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q4 2024 - Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Amanda Morgan - Chief Commercial Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities Paul Choi - Goldman Sachs Matt Taylor - Jefferies Yuan Zhi - B. Riley Larry Solow - CJS Securities Justin Walsh - Jones Trading Andy Hsieh - William Blair John Vandermosten - Zacks Kemp Dolliver - Brookline Capital Markets David Turkaly - Citizens JMP Operator Good morning. Source: Seeking Alpha Wed, 26 Feb 2025 10:49:28 -0500 Sentiment: Neutral |
| Lantheus (LNTH): A 10x Opportunity in Radiopharmaceuticals Explore the exciting world of Lantheus Holdings (LNTH 1.39%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! Source: The Motley Fool Tue, 25 Feb 2025 19:00:00 -0500 Sentiment: Positive |
| Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D. BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus' strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent. Source: GlobeNewsWire Thu, 30 Jan 2025 08:30:00 -0500 Sentiment: Neutral |
Technicals 52 Week Hi: 126.8899 52 Week Low: 58.16 Beta: 0.377 50 Day MA: 93.3884 200 Day MA: 97.1254 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.048 Qtr Revenue Growth YOY: 0.105 Forward PE: 13.5318 Trailing PE: 22.2569